Medical Device News Magazine

Results of a new Antibacterial Technology from DeBogy Molecular that reduces Bacteria and Deadly Infection in Medical Implants reported in the Journal of Orthopedic Research

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

DeBogy Molecular Inc, a biotech startup that specializes in antimicrobial surface modification, today announced that the study results of their antibacterial compound on medical implants have been published in the prestigious Journal of Orthopedic Research. The study affirms the effectiveness and safety of the DeBogy technology to kill dangerous bacteria that proliferates on the surface of a medical implant following surgery. https://onlinelibrary.wiley.com/doi/epdf/10.1002/jor.25638

Surgical site infections resulting from bacterial biofilm on the surface of a medical implant represent one of the most serious complications that can follow orthopedic surgery or the implantation of a medical device. Implant-related infections account for over half of the 2 million healthcare-associated infections annually in the U.S., at a cost of over $27 billion dollars.

The Journal of Orthopedic Research reports on a landmark in vivo study that shows bacterial biofilm in animals using DeBogy-treated implants was reduced by 99.9% vs the control group, 7 days following surgery. Infection in the surrounding tissue in animals using DeBogy-treated implants was reduced by 99.8%. Overall, the animals with DeBogy-treated implants were found to be healthier vs the control group, with measurable decreases in inflammation, fibrosis, vascularization, and necrosis.

“The promise of a new antibacterial technology that can fight infection without antibiotics, chemicals, or temporary coatings is truly transformational,” said Wayne Gattinella, CEO of DeBogy Molecular. “The possibilities of the DeBogy platform to improve the quality of life and reduce the cost of care for millions of people are enormous.”

(Farmington, CT) June 27, 2023- DeBogy Molecular Inc, a biotech startup that specializes in antimicrobial surface modification, today announced that the study results of their antibacterial compound on medical implants have been published in the prestigious Journal of Orthopedic Research. The study affirms the effectiveness and safety of the DeBogy technology to kill dangerous bacteria that proliferates on the surface of a medical implant following surgery. https://onlinelibrary.wiley.com/doi/epdf/10.1002/jor.25638

“The DeBogy technology has the potential to revolutionize the way we prevent and treat surgical site infection.” said Dr Houssam Bouloussa, spine surgeon and cofounder, DeBogy Molecular. “With more than 15 years of development behind us, we are extremely proud to have our proprietary innovation recognized in the Journal of Orthopedic Research.”

The report is published in the June 2023 issue of the Journal of Orthopedic Research. The Journal of Orthopedic Research is a peer-reviewed medical publication of the Orthopaedic Research Society (ORS). The journal is the forum for the rapid publication of high quality reports of new information on the full spectrum of orthopedic research, including life sciences, engineering, translational, and clinical studies.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”